AbTis Co., Ltd. (앱티스) is a South Korean biotechnology company founded in 2016 and headquartered in Yongin-si, Gyeonggi-do, inside the Dong-A Socio Holdings R&D Center. It develops AbClick, a third-generation site-selective antibody conjugation platform that attaches payloads to the Fc Lys248 residue of native IgG antibodies with no enzyme and no Fc engineering, giving a controlled drug-to-antibody ratio and batch-to-batch consistency across ADC, DAC, AOC, ARC, ISAC and dual-payload designs. AbTis licenses the platform, runs collaborative research and fee-for-service ADC development, and advances its own pipeline led by AT-211, a Claudin 18.2-targeting MMAE ADC. Acquired by Dong-A ST in 2023, it now operates as that company's ADC-specialised subsidiary. Its product is licensed chemistry and drug intellectual property, not software: it runs no developer program, public API, SDK or machine-readable contract.
AbTis is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Antibody-Drug Conjugates, and Bioconjugation.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Show this score on your site.
It updates itself when the score changes. Paste this where you link to your API docs:
<a href="https://apis.io/providers/abtis2772/"><img src="https://apis.io/badge/abtis2772/card.svg" alt="AbTis on APIs.io — Kin Score by API Evangelist"></a>
Other styles, a README pill and a shields.io endpoint are on the badge page.
Raise your score.
Agent readiness — checks not met, largest first (exact, from this profile):
Machine-Readable Auth+10 pts — a served openid-configuration/oauth-authorization-server carrying `issuer` (served), else the securitySchemes class in the provider OpenAPIs — bound (mutualTLS, DPoP, Signature) > negotiable (oauth2 authorizationCode/clientCredentials, openIdConnect) > bearer (http bearer, apiKey)
Idempotency+9 pts — OpenAPI mutating operations declare an idempotency key — a header, a request-body property, or a named de-duplication token whose own description says so (verified); else common[].type matches /idempoten/i (documented)
Stable Error Semantics+8 pts — OpenAPI $refs a shared error schema across 4xx/5xx responses (verified), else common[].type includes ErrorCatalog / ErrorCodes / DeclineCodes
13 more unmet checks in the Agent Readiness table above.
Kin Score — facets with the most composite points still available (weight × headroom):
aid: abtis2772
name: AbTis
description: 'AbTis Co., Ltd. (앱티스) is a South Korean biotechnology company founded in 2016 and headquartered in Yongin-si,
Gyeonggi-do, inside the Dong-A Socio Holdings R&D Center. It develops AbClick, a third-generation site-selective antibody
conjugation platform that attaches payloads to the Fc Lys248 residue of native IgG antibodies with no enzyme and no Fc engineering,
giving a controlled drug-to-antibody ratio and batch-to-batch consistency across ADC, DAC, AOC, ARC, ISAC and dual-payload
designs. AbTis licenses the platform, runs collaborative research and fee-for-service ADC development, and advances its
own pipeline led by AT-211, a Claudin 18.2-targeting MMAE ADC. Acquired by Dong-A ST in 2023, it now operates as that company''s
ADC-specialised subsidiary. Its product is licensed chemistry and drug intellectual property, not software: it runs no developer
program, public API, SDK or machine-readable contract.'
url: https://raw.githubusercontent.com/api-evangelist/abtis2772/refs/heads/main/apis.yml
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
gated: private
gated_source:
- x-api-posture
label: Unknown
confidence: low
probe_state: none
source:
- security
generated: '2026-11-06'
method: derived
image: https://abtis.co.kr/assets/favicon/favicon-96x96.png
x-type: company
x-source: harvest:secondary-market
x-harvest-source-url: https://equityzen.com/company/abtis2772/
x-tier: stub
x-tier-reason: harvest
x-legal-name: AbTis Co., Ltd.
x-parent-company: Dong-A ST
x-api-posture: no-product-api
x-api-posture-basis: observed
x-api-posture-note: AbTis licenses ADC linker chemistry and sells laboratory services; its only web property is a gnuboard5
corporate marketing site at abtis.co.kr whose entire navigation is Company, Science, Business and News. No developer portal,
API reference, OpenAPI, GraphQL, AsyncAPI, MCP server or agent card exists on any host it controls, no package named abtis
is published to npm or PyPI, and github.com/abtis is an unrelated individual account, not a company organization.
specificationVersion: '0.20'
created: '2026-09-06'
modified: '2026-09-06'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Antibody-Drug Conjugates
- Bioconjugation
- Drug Discovery
- Oncology
- Life Sciences
- Healthcare
- South Korea
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/abtis2772-domain-security.yml
- type: LLMsTxt
url: llms/abtis2772-llms.txt
- type: Website
url: https://abtis.co.kr/en/
- type: SecondaryMarket
url: https://equityzen.com/company/abtis2772/
- type: About
url: https://abtis.co.kr/en/company/overview.php
- type: Contact
url: https://abtis.co.kr/en/company/contact.php
- type: PressReleases
url: https://abtis.co.kr/en/pr-center/press-release.php
x-enrichment:
date: '2026-09-06'
status: minimal
artifacts_added: 3
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: 'AbTis sells ADC linker chemistry — AbClick platform licences, collaborative research and fee-for-service conjugation
work — so there is no software product to expose: its only web property is a gnuboard5 corporate site whose entire navigation
is Company, Science, Business and News, and behind the site''s CUPID JavaScript cookie challenge (which answers HTTP 200
with a ~780-byte script on every path, then the real status on the cookied retry) /openapi.json, /swagger.json, /api-docs,
/graphql, /llms.txt, /robots.txt, /sitemap.xml and all eight /.well-known/ paths return a genuine Apache 404.'
evidence:
- url: https://abtis.co.kr/en/
status: 200
- url: https://abtis.co.kr/openapi.json
status: 404
- url: https://abtis.co.kr/swagger.json
status: 404
- url: https://abtis.co.kr/graphql
status: 404
- url: https://abtis.co.kr/.well-known/agent-card.json
status: 404
- url: https://abtis.co.kr/.well-known/api-catalog
status: 404
- url: https://abtis.co.kr/llms.txt
status: 404
- url: https://www.abtis.co.kr/openapi.json
status: 403
- url: https://registry.npmjs.org/-/v1/search?text=abtis
status: 200
checked: '2026-09-06'
Calls without X-API-Key need no key. Calls with it need a paid plan — get a key.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.